A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants

In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.
In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):
Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.
The main questions researchers want to answer are:
* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.
Each participant will be in the study for about 22 weeks.

开始日期2025-01-02

申办/合作机构

Biogen, Inc.

NCT06044337

/ Enrolling by invitation临床3期

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301.
The main objective of the study is to learn more about the long-term safety of litifilimab.
The main question researchers want to answer is:
* How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are health problems that may or may not be caused by the study drug.
Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab.
The study will be done as follows:
* The last visit of parent study 230LE301 will be the first visit of study 230LE305.
* All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug.
* Globally, the treatment period will last up to 208 weeks, or 4 years. Participants will have up to 53 study visits during this time.

开始日期2023-10-03

申办/合作机构

Biogen, Inc.

NCT05531565

/ Active, not recruiting临床2/3期

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms and signs of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
The main questions researchers want to answer are:
* How many participants have a score of 0 or 1 on the CLA-IGA-R looking at skin redness after treatment?
* How many participants have their skin disease activity go down by at least 70% as measured by CLASI?
Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and CLE have on the quality of life of participants using a group of questionnaires.
The study will be split into 2 parts - Part A and Part B. Both parts will be done as follows:
* After screening, participants will be randomized to receive either litifilimab or placebo for the 1st treatment period. A placebo looks like the study drug but contains no real medicine.
* Participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks.
* The 1st treatment period will be double blinded which means neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo.
* This double blinded treatment period will last 24 weeks, after which the 2nd treatment period will begin.
* During the 2nd treatment period, all participants will receive litifilimab for 28 weeks.
* After completing treatment in this study, participants that qualify will be given the choice to join the Long-Term Extension study, 230LE305. If they do not, they will move into a follow-up safety period that will last up to 24 weeks.
* The total study duration for participants will be up to 80 weeks.

开始日期2022-09-13

申办/合作机构

Biogen, Inc.

100 项与利替非利单抗相关的临床结果

登录后查看更多信息

100 项与利替非利单抗相关的转化医学

登录后查看更多信息

100 项与利替非利单抗相关的专利（医药）

登录后查看更多信息

项与利替非利单抗相关的文献（医药）

2026-10-01·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST

Article

作者: Chong, Benjamin F ; Chasset, Francois ; Carroll, Hua ; Pournara, Effie ; Yang, Weihong ; Morand, Eric F ; Werth, Victoria P ; Schindelar, Michael ; Merola, Joseph F ; Fivenson, David ; Nyberg, Filippa ; Li, Qianyun

BACKGROUND:

Cutaneous lupus erythematosus (CLE) is a serious autoimmune disease with no approved targeted treatments.

OBJECTIVE:

Evaluate the efficacy and safety of litifilimab in AMETHYST Part A (Phase 2).

METHODS:

AMETHYST is a randomized, double-blind, placebo-controlled, Phase 2/3 study that investigates litifilimab in participants with CLE. Participants were randomized to receive litifilimab 225 mg or placebo every 4 weeks during Weeks 0-24. The primary endpoint was the Cutaneous Lupus Activity Investigator's Global Assessment-Revised (CLA-IGA-R) erythema score of 0-1 at Week 16, with several Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-based endpoints at Week 24 as secondary endpoints. Safety was also assessed.

RESULTS:

Significantly more participants treated with litifilimab achieved clear/almost clear skin (CLA-IGA-R erythema 0-1) than those treated with placebo at Week 16 (14.7% vs 2.9%, P= .0263). Additionally, more participants treated with litifilimab achieved CLASI-70 response vs placebo at Week 24 (21.7% vs 5.8%, P = .0195). Litifilimab was generally well tolerated; safety data were consistent with prior studies.

LIMITATIONS:

Study was not powered to detect statistically significant differences in secondary endpoints.

CONCLUSION:

Litifilimab treatment led to greater improvements in skin disease activity vs placebo and was well tolerated in participants with CLE through Week 24.

2026-10-01·JOURNAL OF INTERNAL MEDICINE

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Review

作者: van Vollenhoven, Ronald

Abstract:

Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides. However, a major change in this situation is currently taking place. Over the past few years, several new biological therapeutics have been approved for the treatment of SLE (belimumab and anifrolumab) or specifically for its renal organ manifestation (obinutuzumab), along with one new small molecular treatment for the latter (voclosporin). Several additional biologicals (litifilimab and dapirolizumab) and small molecules (deucravacitinib, upadacitinib, and cerenimod) are in late‐stage clinical development. Moreover, multiple case series and case reports have been published in the past years demonstrating excellent individual results following treatments aimed at fully depleting B lymphocytes using chimeric antigen receptor bearing T cells (CAR‐T cells) or bi‐specific T‐cell engagers. These reports have raised hopes that not only solid disease control, but also a more profound state of immunological reset—deep remission—can be attained in at least some patients. In this narrative review, these developments will be described, emphasizing both the promises and the challenges they bring about, leading into some predictions of where they may lead to. A reasonable expectation is that in the coming 1–2 years, several additional biologicals and small‐molecular agents will be approved for the treatment of lupus. The most important conclusion is that the future for our patients with lupus looks brighter than ever before.

2026-10-01·Dermatology and Therapy

Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review

Review

作者: Jonnalagadda, Anshu ; Yildiz-Altay, Ummuguslum ; Vesely, Matthew D ; Pathak, Gaurav N ; Richmond, Rhys L ; Gehlhausen, Jeffrey R ; Desai, Amar D

BACKGROUND:

Discoid lupus erythematosus (DLE) is the most common chronic form of cutaneous lupus erythematosus and can lead to scarring, dyspigmentation, and permanent alopecia. The disease often causes visible disfigurement and has a substantial psychosocial impact. Although many patients respond to standard treatment, a subset continues to experience persistent or relapsing disease that remains difficult to control.

METHODS:

A focused literature search was performed using PubMed, Google Scholar, Web of Science, and Scopus to identify English-language studies published from January 1990 through October 2025. Search terms included "discoid lupus erythematosus," "cutaneous lupus erythematosus," "chronic cutaneous lupus," "pathogenesis," "therapy," "antimalarial," "immunosuppressant," "biologic therapy," "JAK inhibitor," "small molecule therapy," and "targeted therapy." Recent clinical trials, consensus guidelines, and review articles were prioritized. Reference lists of key publications were manually screened to capture additional relevant studies.

RESULTS:

Current first-line topical pharmacotherapeutic treatment options of DLE include photoprotection, topical corticosteroids, and calcineurin inhibitors for localized disease, and antimalarial therapy as a first-line systemic treatment. For refractory disease, systemic immunosuppressants remain common second-line options. Emerging therapies targeting interferon and cytokine signaling pathways, including anifrolumab, belimumab, and tyrosine kinase (TYK2) inhibitors such as deucravacitinib and the plasmacytoid dendritic cell modulators litifilimab and daxdilimab have shown early promise in improving cutaneous disease activity in patients with refractory DLE. Procedural modalities such as laser therapy are being studied as adjuncts for scarring and dyspigmentation.

CONCLUSIONS:

Ongoing advances in understanding the immune mechanisms underlying DLE are shaping a transition from broad immunosuppression toward more targeted treatment strategies. Integrating newer biologic and small-molecule therapies with conventional management may offer improved control and better long-term outcomes for patients with chronic disease.

177

项与利替非利单抗相关的新闻（医药）

2026-10-31

·自免药研社

狼疮新药开发的最大陷阱：SRI-4/BICLA、安慰剂效应与入组异质性

摘要：同一个药、同一批临床数据，终点从 SRI-4 换成 BICLA，一个"阴死"、一个获批；另一个药 II 期 62% 对 33%，III 期却被安慰剂组反超。狼疮新药开发的三大陷阱——复合终点、安慰剂效应、入组异质性——到底哪个才是真正的翻车点？这篇用十几个 III 期真实数据，把链条拆给你看。 🔬一、先看两个很难解释的现象先讲两件反常识的事。第一件：安慰剂把药"反超"了。 Ustekinumab（抗 IL-12/23 单抗，银屑病、克罗恩病的明星药）在狼疮 II 期做得非常漂亮：102 名患者，主要终点 SRI-4 应答 62% 对安慰剂 33%。带着这样的底气进入 III 期 LOTUS（516 人，3:2 随机），结果却在预设的期中分析后提前终止——在完成随访的分析人群里，治疗组 SRI-4 应答 44%，安慰剂组反而高达 56%。一个机制上"应该有效"的药，在 III 期连安慰剂都打不过。第二件：换一个终点，命运反转。 Anifrolumab（I 型干扰素受体拮抗剂）的 TULIP-1（457 人）用 SRI-4 做主要终点，300 mg 组应答 36.2%，比安慰剂组的 40.4% 还低，试验"看起来死透了"。但同一批数据里，预设的次要终点 BICLA 却出了信号（37.1% 对 27.0%）。阿斯利康随即把 TULIP-2 的主要终点从 SRI-4 改成 BICLA——结果 BICLA 应答 47.8% 对 31.5%（P=0.001），获批上市。同一个药、同一类数据，只换一个终点，命运天壤之别。这说明什么？SRI-4/BICLA 终点、安慰剂效应、入组异质性——这三件事不是三个独立问题，而是一台环环相扣的"翻车机"。这篇文章用可溯源的公开 III 期数据，拆清楚每一环怎么咬合，以及哪一环最容易让人翻车。 🔬二、先把链条立起来：病根—放大器—生死门在追问"哪一环最容易翻车"之前，先厘清三件事各自的位置： •入组异质性（病根）：SLE（系统性红斑狼疮，Systemic Lupus Erythematosus）不是一种病，而是多种免疫通路紊乱叠加的"伞形病"。单机制药物只打其中一条通路，入组越杂，真正响应的人越少，全人群效应被摊得越薄。 •安慰剂效应（放大器）：狼疮试验几乎都允许对照组继续用背景激素＋免疫抑制剂，且招募天然偏向皮肤、关节这类"好改善"的轻中度器官。两臂一起往好走，安慰剂应答被抬到 35%–40% 甚至更高。 •终点设计（生死门）：SRI-4/BICLA 都是"二分类＋多器官打包"的粗粒度复合终点，而狼疮新药的真实效应量往往只有 10–16 个百分点，刚好压在统计噪声线上。终点一选错，或读不出它擅长的维度，信号就过不了这道门。三者互为因果：异质性抬高安慰剂应答 → 安慰剂把效应量摊薄 → 粗终点又吞掉一部分真实信号 → 统计功效崩盘、试验"翻车"。所以"哪一环最容易翻车"，其实是在问：这台机器最脆弱的咬合点在哪。 🔬三、终点是什么，盲区又在哪里？ SRI-4 与 BICLA：两个"二分类复合终点" 维度 SRI-4（SLE Responder Index） BICLA（BILAG-based Composite Lupus Assessment）核心工具 SLEDAI-2K 积分（SELENA-SLEDAI） BILAG-2004 器官系统分级（A/B/C/D）应答定义 ①SLEDAI 较基线下降 ≥4 分；②无新发 BILAG A、且最多 1 个新发 BILAG B；③PGA 无恶化 ①至少 1 个器官系统 BILAG 较基线改善（A→C/D 或 B→C/D）；②其余系统无恶化、无新发 A 级；③PGA 恶化 <10%，SLEDAI 无恶化，无方案禁止的合并用药变动判断单位总分器官系统代表使用 belimumab BLISS-52/76；anifrolumab TULIP-1 anifrolumab TULIP-2；epratuzumab EMBODY （注：SRI-4 中的 SLEDAI 指 SLE Disease Activity Index 2000，BILAG 指 British Isles Lupus Assessment Group，PGA 指 Physician Global Assessment。） SRI-4 的四个盲区 1.二分类、无中间态：是/否两档，80% 的改善和"刚好够 4 分"都算响应，程度信息被丢弃； 2.被总分主导：只看 SLEDAI 总分降 4 分，各器官不设权重，单一器官的部分改善常被淹没； 3.低基线患者容易"达标"：基线 SLEDAI 只有 6 的患者降 4 分就够响应，门槛偏低、易掺假阳性； 4.对肾、神经精神等"重器官"不敏感：SLEDAI 的肾/神经条目权重不足，这部分疗效常测不出来——这也是狼疮肾炎（LN）要单做肾脏终点（如完全肾脏应答 CRR）、不套用 SRI-4 的原因。 BICLA：纠偏，但不是万能 BICLA 把判断单位从"总分"换成"器官系统"，能捕捉皮肤、关节、心肺等单器官的改善，这正是 TULIP-2 选它做主终点、以及它能读出 anifrolumab 信号的原因。但它同样是二分类复合终点，安慰剂应答并不低——epratuzumab 的 EMBODY 里，安慰剂组 BICLA 应答都有 34%。结论：终点不是"越精细越好"，而是"与药物机制、目标人群、安慰剂背景匹配"。维度选错，就是前两道门之外、决定生死的第三道坎。被终点与人群"杀死"的经典：rituximab 最能说明"终点＋人群不匹配"代价的，是抗 CD20 的 rituximab。它在非肾炎的中重度狼疮里做了 EXPLORER（Merrill, 2010），又在增殖性狼疮肾炎里做了 LUNAR（叠加吗替麦考酚酯，Rovin, 2012）——两个 III 期都没有达到主要复合终点：LUNAR 里，完全＋部分肾脏应答 56.9% 对安慰剂 45.8%，无统计学差异。但机制并非全无信号——LUNAR 中 B 细胞耗竭充分（72 例中 71 例 CD19+ 耗竭），血清 C3/C4、抗 dsDNA 均显著改善，事后亚组分析还显示非洲裔、西班牙裔患者的应答更集中。这件事的教训是双重的：一是异质性人群里，全人群二分类终点读不出一个"只对部分患者有效"的机制；二是同一个药，指标上"打中了靶点"（血清学改善），却未必能在粗终点上转化为全人群获益。这提示：若当年能用标志物富集人群、用更硬的器官终点来读，结局或许不同。它和 ustekinumab、baricitinib 的结局，是同一种病根的不同表现。 🔬四、安慰剂效应：狼疮为什么是"重灾区" 一组可溯源的 III 期数据（证据链）试验（药物/机制）主要终点治疗组应答安慰剂应答差结局 BLISS-52（belimumab 10 mg，抗 BLyS） SRI-4 57.6% 43.6% +14.0 阳性（首个获批生物药） BLISS-76（belimumab 10 mg） SRI-4 43.2% 33.5% +9.7 阳性（仅 10 mg 达显著） TULIP-1（anifrolumab 300 mg，抗 IFNAR） SRI-4 36.2% 40.4% −4.2 失败 TULIP-1（同试验）预设次要终点 BICLA 37.1% 27.0% +10.1 出信号 TULIP-2（anifrolumab 300 mg） BICLA 47.8% 31.5% +16.3 阳性（获批） EMBODY-1（epratuzumab 1200 mg，抗 CD22） BICLA 39.8% 34.1% +5.7 失败 LOTUS（ustekinumab，抗 IL-12/23） SRI-4 44% 56% −12 失败（提前终止） SLE-BRAVE-I（baricitinib 4 mg，JAK1/2 抑制剂） SRI-4 达主终点对照 — 主终点阳/次要全落空 SLE-BRAVE-II（baricitinib 4 mg） SRI-4 未达标 — — 失败 ILLUMINATE-2（tabalumab Q2W，抗 BAFF） SRI-5 38% 28% +10 主终点达/仍被终止 AURORA-1（voclosporin，钙调磷酸酶抑制剂） LN 完全肾脏应答 CRR 41% 22.5% +18.5 阳性（获批）（注：本表为跨试验间接比较，人群与统计口径不同，仅用于说明"安慰剂应答水平"这一现象，勿作头对头解读。）读这张表，有三个残酷事实： 1.安慰剂应答普遍高达 28%–56%。狼疮的"背景标准治疗"（激素、免疫抑制剂、抗疟药）把两臂一起抬高； 2.真实效应量多数只有 +10 到 +16 个百分点，小到可以栽在任何一处偏倚或一次抽样波动里； 3.即便"阳性"，也常是险胜：SLE-BRAVE-I 主终点过了、关键次要终点全落空，SLE-BRAVE-II 干脆全盘皆输——同机制同剂量的可重复性极差。安慰剂为什么这么高：四个原因 •背景 SOC 允许：出于伦理，对照组不可能只吃安慰剂，通常叠加激素（EMBODY 甚至强制 5–60 mg/天）＋免疫抑制剂＋抗疟药，两臂都在好转； •回归均值（regression to the mean）：入组要求"当前处于活动期"，而活动期本身有自发回落倾向，对照组因此跟着"好转"； •招募偏倚：皮肤、关节是最常见也最好改善的器官，而严重的肾、神经精神系统狼疮常被排除在外，等于把"最容易起效、波动最大的病人"堆给了安慰剂组； •激素方案干扰：不少试验还强制或鼓励激素减量，进一步模糊组间差异。统计后果是直接而残酷的：统计功效崩塌。狼疮领域 2018 年"社区共识小组"直言：单一生物制剂的疗效天花板可能只有 40%–60%，而安慰剂应答却高达 35%–40%，在这样的条件下多数试验"难以成立"。一个对照锚点：狼疮肾炎为什么更容易读出信号把狼疮肾炎和"全身 SLE"放在一起看，差异会非常直观。AURORA-1（voclosporin）的完全肾脏应答差值是 +18.5 个百分点（41% 对 22.5%），是狼疮领域迄今少见的大效应量——而它恰恰发生在三个条件同时满足的适应症里： 1.人群最窄：只入组 III/IV（±V）型或 V 型狼疮肾炎，排除了一大堆"轻中度皮肤/关节"噪声； 2.终点最硬：完全肾脏应答要同时看蛋白尿下降、肾功能稳定、以及糖皮质激素的减量，是"硬到很难靠回归均值混过去"的终点； 3.安慰剂最低：因为肾脏终点不易自发改善，安慰剂应答被压到 22.5%。反观全身 SLE 的 SRI-4/BICLA，安慰剂应答普遍 28%–56%，效应量只有 10–16 个百分点。同样的药，放进"更窄的人群＋更硬的终点"，信号就能被放大——这是从反面印证：安慰剂效应不是不可战胜的，而是被"人群太宽、终点太软"喂大的。 🔬五、入组异质性：一切的病根如果安慰剂是"放大器"，那异质性就是"源头"。先看清 SLE 的底色：它主要影响育龄期女性，男女发病比可达 9:1，且在黑人、西班牙裔人群中患病更重、更常见。不同患者之间，可能是皮肤红斑、关节炎、狼疮肾炎、神经精神症状或血液学异常的任意组合——这本身就决定了，任何"打一条通路"的靶向药，都只对其中一部分人成立。把这样一批人塞进一个全人群试验，效应被摊薄几乎是必然的。层面异质性表现对试验的杀伤临床层面皮肤型、关节型、狼疮肾炎、神经精神狼疮、血液学异常——器官谱不同对同一种药响应差异大，全人群效应被摊薄血清学层面抗 dsDNA 阳性/阴性、补体 C3/C4 高低活动性血清学亚群对靶向药响应更集中，混入阴性者拉低均值通路/分子层面 I 型干扰素高/低基因标签、浆母细胞驱动、T/B 细胞失衡单机制药只打一条通路，只有亚群响应异质性为什么致命，三条逻辑： 1.单机制药只打一条通路：混合入组后只有亚群响应，全人群效应被平摊，效应量骤降； 2.异质性人群的安慰剂背景更乱：组间变异更大，检验灵敏度进一步被压缩； 3.种族/民族差异：狼疮在黑人、西班牙裔人群中患病更重、更常见，若入组失衡，还可能把"人群偏倚"伪装成"疗效差异"，误导研发决策。 🔬六、哪一环最容易翻车？（核心判断）我的判断是：最容易翻车的，既不是异质性本身，也不是安慰剂本身，而是"终点测量 × 安慰剂应答"共同决定的统计功效——这道生死门。异质性是病根、安慰剂是放大器，但它们最终都是通过同一个机制杀死试验：让真实效应量小到落在噪声线以下，一次抽样就能翻转结果。而终点，就是决定这条噪声线在哪、以及信号能不能被读出来的那道闸门。三条证据支撑这个判断： 1.同一药物、不同终点的命运反转（TULIP-1 失败 / TULIP-2 获批）：药物本身很可能有效，但粗终点读不出来。终点这道门，能直接给一个有效机制判死刑； 2.同一机制、不同试验的可重复性崩塌（baricitinib：I 期成、II 期败；ustekinumab：II 期强、III 期被安慰剂反超）：说明真实效应量小到一次抽样就能翻转，这是"安慰剂＋异质性"把信号压到噪声线下的直接后果； 3.终点是最可干预的一环：你改变不了疾病固有的异质性，也难以在伦理约束下压掉背景 SOC，但你可以换终点、可以富集人群、可以选对目标器官。翻车最集中的地方，恰恰是你可以动手的地方。结论一句话：异质性是病根，安慰剂是放大器，而终点设计是那道决定生死的门——绝大多数狼疮 III 期，都是死在这道门上。 🔬七、怎么避免翻车：2025–2026 正在发生的事对策具体做法在研/在售例子终点创新从"全人群二分类"转向低疾病活动度（LLDAS）、缓解（DORIS）、器官特异终点 litifilimab（BIIB059，抗 BDCA2，靶向浆样树突状细胞 pDC）2026 年 1 月获 FDA 突破性疗法认定，专门针对皮肤狼疮（CLE），以皮肤 CLASI 评分为主终点——收窄适应症＋选对终点，而不是在全人群硬拼 SRI-4 生物标志物富集用 I 型干扰素基因标签、抗 dsDNA/补体、pDC 通路等"挑病人" anifrolumab 在干扰素高表达亚群应答更高（TULIP-2 中达 48.0%）；deucravacitinib（TYK2 抑制剂）II 期在症状/生活质量改善上阳性，两项 III 期进行中设计约束限制背景激素用量、富集高活动度人群、预设激素减量规则 BLISS-SC 高活动度亚组、TULIP 系列强制激素减量方案可重复性验证 III 期前对效应量与安慰剂背景做更保守假设，避免"II 期虚高、III 期反超" 社区共识小组呼吁的统计设计改进把这套思路落到当下，有三个"最接近正确范式"的样本值得对照： •anifrolumab（TULIP）：是"标志物富集＋换终点"的活教材。它在 TULIP-1 上"失败"、TULIP-2 上"成功"，靠的不是新机制，而是把主终点换成更能读出器官级改善的 BICLA，并且在干扰素高表达亚群里信号更集中（48.0%）； •voclosporin（AURORA-1）：是"人群切窄＋终点做硬"的样本。它把适应症锁定在狼疮肾炎、用完全肾脏应答做主终点，换来狼疮领域少见的大效应量； •litifilimab（BIIB059）：是"机制精准＋适应症收窄"的前瞻样本。它靶向浆样树突状细胞上的 BDCA2，直接压制 I 型干扰素上游，2026 年 1 月获 FDA 突破性疗法认定，并先聚焦于皮肤狼疮（CLE）这个"异质性最低、终点最明确"的细分人群。它押的赌注，正是本文说的那套逻辑：先缩小异质性，再读出信号。 🔬八、结尾：把链条放回一条线上留给读者的"三问"自查框架以后看任何一份狼疮 III 期方案，不必先被几十页的统计计划吓住，先问自己三个问题： 1.机制：这个药打的是哪条通路？这条通路在目标人群里覆盖多少人？如果异质性太宽，效应必然被摊薄； 2.安慰剂：试验允许的背景激素/免疫抑制剂会是多少？对照组会不会"一起好转"？如果安慰剂应答被估到 35% 以上，而效应量只有 10 个百分点，这个试验就站在悬崖边； 3.终点：主终点能读出这个药最擅长的器官/维度吗？如果只能读总分，单器官的改善会不会被埋掉？它匹配的是机制，还是只是"大家都在用"的默认选项？三个答案里只要有一个是"不确定"，这个 III 期就处于翻车线上——因为狼疮的真实效应量，本来就只比统计噪声大一点点。把这三件事放回一条链上看，真正的研发动作应该是：先识别你的药打哪条通路（缩小异质性）→ 再用生物标志物富集该亚群（压低噪声）→ 最后为这个亚群选一个读得出来的终点（跨过生死门）。三步都要对，但最常被忽略、也最可挽救的，是终点这一环。备注：本文的所有判断都建立在"效应量 ≤16 个百分点、安慰剂 ≥28%"这一现实之上；如果未来出现效应量明显更大、或安慰剂应答显著被压低的疗法，这条链的脆弱点也会随之移动。当下的教训是确定的：在狼疮这种高异质性、高安慰剂应答的疾病里，把终点和人群想清楚，比把机制讲得漂亮更重要。数据来源 •BLISS-52/76：Furie R, et al. Arthritis Rheum. 2011；GSK 2009 ACR 披露（57.6% vs 43.6% 等） •TULIP-1：Furie R, et al. Lancet Rheumatol. 2020（SRI-4 36.2% vs 40.4%；BICLA 37.1% vs 27.0%） •TULIP-2：Morand EF, et al. N Engl J Med. 2020（BICLA 47.8% vs 31.5%，P=0.001；干扰素高表达亚群 48.0%） •EMBODY-1/2：Clowse MEB, et al. Arthritis Rheumatol. 2017（BICLA 33.5%–39.8%，无显著差异） •LOTUS：van Vollenhoven R, et al. Ann Rheum Dis. 2022（SRI-4 44% vs 56%，提前终止） •SLE-BRAVE-I/II：Morand EF, et al. Lancet. 2023；Eli Lilly 2022 公告；ClinicalTrials.gov NCT03616964 •ILLUMINATE-2：Isenberg D, et al. 2015；Eli Lilly 2014 终止公告 •rituximab（EXPLORER/LUNAR）：Merrill JT, et al. Arthritis Rheum. 2010；Rovin BH, et al. Arthritis Rheum. 2012 •AURORA-1：Rovin BH, et al. Lancet. 2021（CRR 41% vs 22.5%，OR 2.7） •安慰剂背景/疗效天花板：Lupus Community Panel proposals 2018（Lupus Sci Med） •litifilimab：Biogen 2026-01 突破性疗法认定公告（CLE）；AMETHYST（NCT05531565）免责声明本文为自身免疫疾病药物研发领域的方法学观察与数据分析，仅面向行业专业读者，不构成医疗建议、诊疗指导或任何投资决策依据。三抗挑战达必妥：Tilrekimig 全球头对头 III 期启动，IL-4/IL-13/TSLP 三阻断能颠覆 Dupilumab 吗？全球进展最快、进入注册阶段的自免领域siRNA-Cemdisiran_NIMBLE研究回溯与补体通路自免siRNA管线全景 RIPK1https://mp.weixin.qq.com/s/UEmtMLcUUBmtZ9lK-y2BgQ 抑制剂自免炎症临床复盘：细胞坏死通路，II期关节炎试验阴性，靶点机制与临床转化的鸿沟利妥昔单抗做不成的，奥妥珠单抗凭什么做成了？——II型抗CD20在狼疮的"全域突围" IL-23 p19靶点古塞奇尤单抗（Guselkumab）：从银屑病到IBD全线扩张，肛周瘘管性克罗恩病迎来里程碑突破 II 期数据亮眼，Riliprubart 能否跨过 CIDP 的 III 期陷阱？ IFNAR1靶点阿伏利尤单抗：I型干扰素通路在系统性红斑狼疮中的亚洲人群验证全球进展最快、进入注册阶段的自免领域siRNA-Cemdisiran_NIMBLE研究回溯与补体通路自免siRNA管线全景利妥昔单抗做不成的，奥妥珠单抗凭什么做成了？——II型抗CD20在狼疮的"全域突围" RIPK1抑制剂自免炎症临床复盘：细胞坏死通路，II期关节炎试验阴性，靶点机制与临床转化的鸿沟 III 期顶线阳性！VC005 会是自免 AD 的国产答案吗？狼疮新药以后都要做生物标志物富集试验吗？从一个IIb的成与败说起三项III期全达标却主动终止！Amlitelimab折戟AD：OX40赛道真的走不通了？破局干燥综合征：BAFF/APRIL 通路之争与 B 细胞靶向疗法的二十年救赎从肿瘤到自免的跨界革命：BTK抑制剂如何重塑自身免疫疾病治疗格局自免 License-out 潮：15 亿美元纸面对价背后，中国小分子出海的收益与暗礁自免领域并购的底层逻辑是什么？回溯: 武田40 亿美元收购 Zasocitinib：重金押注 TYK2 罕见自身免疫领域-CIDP全球跨国药企研发进展 BTK 抑制剂在 SLE 屡战屡败：B 细胞指标显著下降，为什么临床终点却无法达标？辉瑞PF‑06835375（抗CXCR5单抗）：系统性红斑狼疮Ⅰ期临床的机制、数据与靶点定位诺华 ianalumab（BAFF 受体单抗）干燥综合征 III 期数据复盘：无 DMT 的干燥综合征，终于等到获批药物？自免领域深度| IgAN肾病管线扎堆：四大机制路径，谁的临床证据最具确证性？【版权说明】：本公众号欢迎个人分享朋友圈或大群，但媒体或机构权转载需本公众号授权.

临床3期上市批准临床结果临床2期

2026-10-29

·癌友创新药交流群

北京协和牵头、靶向BDCA2：国产狼疮新药HC022进入Ib期临床

系统性红斑狼疮皮肤性狼新一代创新药注射用生物制剂 HC022 是一种注射用生物制品，它是一款靶向 BDCA2 的单克隆抗体类生物药。给药方式为皮下注射，Ib 期试验中设计了 100 mg、225 mg、450 mg 等多个剂量组，给药频率为每 4 周一次。皮下给药相较于静脉输注，对需要长期管理的狼疮患者更为便利。药理机制从源头掐断 I 型干扰素要理解 HC022 的机制，需要先认识 pDC。pDC 是人体内 I 型干扰素最主要的“生产工厂”。在相当比例的 SLE 和 CLE 患者体内，pDC 处于异常活跃状态，持续大量释放 I 型干扰素，驱动皮肤红斑、关节肿痛乃至肾脏损伤等一系列炎症反应。 BDCA2 是几乎只表达在 pDC 表面的一种受体。当药物分子与 BDCA2 结合后，会触发受体向细胞内部“内吞”，相当于给 pDC 贴上“静默标签”，抑制其产生 I 型干扰素以及其他促炎因子。 HC022 正是沿用了这一机制：通过结合 BDCA2，从上游下调干扰素通路，而不是在下游逐一阻断某一种炎症因子。现有的上市药物目前全球狼疮治疗领域已上市的生物制剂主要有两款：靶向 BLyS 的贝利尤单抗和靶向 I 型干扰素受体的阿尼鲁单抗。HC022 与它们的关键区别在于作用位置。贝利尤单抗作用于 B 细胞存活因子，阿尼鲁单抗则是在干扰素“接收端”阻断信号。HC022 选择在干扰素“生产端”下手，理论上能更早地减少多种 I 型干扰素亚型的生成，而非仅阻断某一受体后的信号传导。更具参照价值的是同一靶点的Litifilimab（BIIB059），由渤健开发，是全球 BDCA2 赛道进度最快的药物。其 II 期 LILAC 研究数据显示，Litifilimab 在 CLE 患者中显著降低了皮肤疾病活动度评分，并因此获得美国 FDA 突破性疗法认定。HC022 作为同一靶点的国产候选药物，其潜在优势可能体现在两个方面：一是作为本土开发的生物药，未来在可及性和成本上可能更具竞争力；二是皮下注射的给药方式与 Litifilimab 一致，符合狼疮慢病长期管理的需求。不过需要明确：HC022 尚处于 I 期阶段，相信不久的将来也会造福SLE、CLE患者。国际社会广泛关注受益群体 HC022 的 Ib 期研究由北京协和医院牵头开展。协和医院风湿免疫科在国内狼疮诊疗领域具有标杆地位，由其主导早期临床研究，本身即反映了学术界对该靶点的认可。从更宏观的视角看，BDCA2 靶点在全球范围内被视作狼疮治疗的重要方向之一，Litifilimab 的突破性疗法认定进一步印证了这一判断。HC022 的推进，意味着中国在这一前沿靶点上有了本土候选药物，而非仅仅跟随已上市产品。受益群体方面，HC022 瞄准的是 SLE 和 CLE 患者。中国 SLE 患者约 70 万至 100 万，居全球首位，且发病年龄轻（平均约 30.7 岁），女性占比极高。现有标准治疗中，糖皮质激素和免疫抑制剂仍占据主导，中国患者激素使用率高达 84.13%，远高于全球水平。长期激素暴露带来的感染、骨质疏松等风险，使得对更精准、更安全的靶向药物需求极为迫切。CLE 患者则面临另一重困境：皮肤病变可能导致永久性瘢痕和毁容，而此前全球范围内尚无专门获批的靶向疗法。HC022 若能成功，将为这两类患者提供新的选择。关爱狼疮大爱救助受试者获益：交通补助+误工补助+采血补助+ 营养补助=共计17000左右时光匆匆，步履不停报名资料既往诊断病历；用药证明；血液检查单；试验中心北京、广东、天津、福建、河南、江苏、辽宁、浙江、山东、湖北、河北、上海、四川、陕西、江西等地。关注我们，了解更多临床项目。 #红斑狼疮临床试验 #系统性红斑狼疮临床试验#狼疮患者#SLE#CLE#红斑狼疮女孩

2026-10-28

·Firstwordpharma

CEO says Biogen has 'returned to growth' as newer drugs, Apellis drive Q3 beat

Biogen said Wednesday that third-quarter revenues rose 11% year-over-year to $2.8 billion, beating analyst expectations of $2.6 billion, as its newer medicines, including those added through its $5.6-billion acquisition of Apellis Pharmaceuticals, helped offset declines in its legacy multiple sclerosis (MS) business."Our third-quarter results demonstrate that Biogen has returned to growth," stated CEO Chris Viehbacher. Seven of eight products in the pharma's growth portfolio grew by double digits, including spinal muscular atrophy drug Spinraza (nusinersen), which saw sales jump 23% to $461 million thanks to more patients converting to the high-dose regimen. Analysts were projecting $400 million.IQLIK outpacing IV launchRevenue for Eisai-partnered Alzheimer's treatment Leqembi increased 67% to $202 million – the Japanese drugmaker records global in-market sales of the drug – with $107 million of that in the US. The global figure edged past estimates of $199 million.Moreover, the Leqembi IQLIK subcutaneous formulation – approved for maintenance dosing last year and more recently as an at-home starting dose – has been outpacing Leqembi's original intravenous (IV) launch "by three and a half and [Eli Lilly's] Kisunla by six times," according to Alisha Alaimo, who heads Biogen North America operations, though she cautioned it was still early days.Alaimo noted that while the majority of IQLIK use comes from Leqembi IV prescription writers, Biogen is "now seeing writers who have never written an [anti-amyloid therapy] before, never wrote Kisunla, never wrote [Leqembi IV]. They're writing IQLIK – and we are also seeing physicians who have only ever written Kisunla write IQLIK." She called that "a dynamic change," especially in areas with long drive times, citing the West Coast as the fastest uptake given its geography and the "convenience factor."Apellis momentumMeanwhile, Biogen also reported the first full-quarter of sales for geographic atrophy treatment Syfovre and complement inhibitor Empaveli since the Apellis deal closed in May. Syfovre generated $191 million and Empaveli $52 million, for respective gains of 27% and 92% year-over-year."I think we've really realised a synergy between the folks from Apellis who've joined the Biogen teams," said Viehbacher on an analyst call Wednesday. "They've come together and when I look at Syfovre and Empaveli you can see 37% year-over-year growth of $243 million, that's already on a run rate of $1 billion."Overall, Biogen said the growth portfolio accounted for roughly two-thirds of its core pharmaceutical revenue. MS drug sales fell 13% in the quarter to $919 million.The company is keeping its full-year outlook for mid-single-digit revenue growth in 2026, but raised the lower end of its full-year adjusted earnings guidance by 20 cents, which now falls between $12.20 and $13 per share.Five key readoutsViehbacher also highlighted early-stage work as now being one of Biogen's key priorities, calling it "one of the most important and often most neglected areas of our industry." He admitted "we were not necessarily very good with that" — the company had gone three years without a single IND – but he says there has been "a radical overhaul of the whole research and early development area."The ambition is to have at least 20 programmes in early-stage development over the next few years. "This is a big shift in how we operate because Biogen historically has looked at things on an asset-by-asset basis," Viehbacher said.The company has five registrational study readouts on the horizon over the next year. Two Phase III trials of litifilimab, a IgG1 monoclonal antibody, are due in systemic lupus by year-end, with a third in cutaneous lupus to follow in the first half of 2027. That same half-year should also bring results from a Phase III study of felzartamab, a CD38-targeting antibody in development for antibody-mediated rejection (AMR) in kidney transplant recipients.Phase III results for zorevunersen, an antisense oligonucleotide it is co-developing with Stoke Therapeutics to treat Dravet syndrome, are expected towards the end of next year.

并购临床3期上市批准临床结果寡核苷酸

100 项与利替非利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12232	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤红斑狼疮	临床3期	美国	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	中国	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	日本	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	阿根廷	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	比利时	Biogen Idec Research Ltd.	2023-10-03
皮肤红斑狼疮	临床3期	巴西	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	保加利亚	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	加拿大	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	智利	Biogen, Inc.	2023-10-03
皮肤红斑狼疮	临床3期	哥伦比亚	Biogen, Inc.	2023-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05531565 (AMETHYST, ACR2026)	临床2/3期	皮肤红斑狼疮	93	Litifilimab	顧獵艱鑰選鑰選網觸糧(膚獵壓鹹網蓋構鹹繭觸) = 觸積製壓壓鬱製觸觸憲糧製衊淵遞餘鏇衊鑰蓋 (築繭鹹鬱鹹衊製構廠選 ) 更多	积极	2026-11-06
				Placebo	艱鹽膚衊膚願餘窪淵醖(範選蓋餘淵獵窪齋網鏇) = 願艱窪淵製構夢鏇鑰願鏇膚積膚鏇繭憲築壓壓 (願築夢醖糧製齋糧餘夢 ) 更多
NCT02847598 (LILAC \| LILAC study, CTgov)	临床2期	皮肤红斑狼疮 \| 系统性红斑狼疮 \| 盘状红斑狼疮	264	Placebo (Part A: Placebo)	觸遞壓糧鏇窪獵襯繭鹹(簾膚觸餘鑰餘膚範鹹膚) = 願糧餘衊醖築壓憲襯鏇襯製選觸襯醖窪鏇窪膚 (獵艱製壓鏇鏇築網齋鑰, 10.3) 更多	-	2023-05-15
				BIIB059 (litifilimab) (Part A: BIIB059 450 mg)	觸遞壓糧鏇窪獵襯繭鹹(簾膚觸餘鑰餘膚範鹹膚) = 鏇餘憲鹽顧構醖鹹蓋壓襯製選觸襯醖窪鏇窪膚 (獵艱製壓鏇鏇築網齋鑰, 8.7) 更多
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	临床2期	系统性红斑狼疮 BDCA2	132	Litifilimab 450 mg	淵製觸壓範範遞選鏇窪(齋構艱築廠鏇鹹願膚窪): P-Value = 0.04 更多	积极	2022-09-08
				Placebo
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	临床2期	皮肤红斑狼疮	132	Litifilimab 50 mg	壓網製鏇遞鹽觸憲襯鬱(壓顧醖壓憲夢糧夢繭餘) = Litifilimab was associated with one case of herpes zoster infection 膚積鹽衊糧衊廠壓醖願 (鏇願襯壓醖餘鹽構網簾 ) 更多	积极	2022-07-28
				Litifilimab 150 mg
NCT02847598 (LILAC study, EULAR2022)	临床2期	皮肤红斑狼疮 BDCA2	-	BIIB059	積簾範艱繭鏇衊膚鑰夢(繭顧觸遞憲範鑰艱壓鏇) = 範壓襯顧鏇衊獵鑰廠範齋範艱艱遞選淵範壓簾 (蓋蓋網齋鏇鹹鹽鹽憲顧 ) 更多	积极	2022-06-01
NCT02847598 (LILAC, EULAR2022)	临床2期	系统性红斑狼疮 anti-nuclear antibodies \| anti-double-stranded DNA antibodies	-	BIIB059 450 mg	鬱鹹繭壓淵範構鏇構觸(餘鹽廠獵網醖簾遞襯積) = 鏇衊製鹹願製廠簾淵窪糧膚築鏇廠襯襯齋壓鬱 (衊窪願醖築廠觸構觸膚 ) 更多	积极	2022-06-01
				Placebo	鬱鹹繭壓淵範構鏇構觸(餘鹽廠獵網醖簾遞襯積) = 簾獵獵衊衊鬱獵遞顧觸糧膚築鏇廠襯襯齋壓鬱 (衊窪願醖築廠觸構觸膚 ) 更多
NCT02847598 (LILAC, ACR2020) 人工标引	临床2期	系统性红斑狼疮	120	BIIB059	觸壓遞糧廠構窪窪窪積(壓醖淵齋願網鹹醖鏇襯) = 鑰艱衊範淵壓顧鑰鑰齋製蓋齋襯構廠觸構艱醖 (窪願築淵夢鑰蓋糧醖鏇, 1.2) 更多	积极	2020-11-07
				Placebo	觸壓遞糧廠構窪窪窪積(壓醖淵齋願網鹹醖鏇襯) = 網廠鹹範選鏇獵範糧鹹製蓋齋襯構廠觸構艱醖 (窪願築淵夢鑰蓋糧醖鏇, 1.3) 更多
NCT02847598 (LILAC, EULAR2020)	临床2期	皮肤红斑狼疮	132	BIIB059 50 mg	繭憲鏇壓鏇鹽積憲構選(膚築鑰夢製觸積醖壓齋) = 62 (62.6%) 80 (60.6%) 鑰蓋製築構選積壓淵鹽 (鑰觸餘築選憲構鹹顧範 ) 更多	积极	2020-06-03
				BIIB059 150 mg
NCT02847598 (Pubmed \| J Pharmacokinet Pharmacodyn)	临床2期	皮肤红斑狼疮	264	BIIB059	鹹觸網齋衊蓋窪壓醖鬱(襯膚鏇顧膚簾糧鏇獵鹽) = 鹽獵膚網夢廠蓋鑰衊網顧夢簾願鏇廠窪齋鏇糧 (構鬱鑰窪窪選衊衊衊衊 ) 更多	-	2020-06-01
NCT02106897 (Pubmed \| J Clin Invest) 人工标引	临床1期	湿疹 \| 系统性红斑狼疮	54	BIIB059	廠網鹽糧範網網膚構鑰(衊獵淵網簾廠築齋鹽鹹) = 願齋鑰襯衊範鏇鹽願願憲範淵壓築築餘壓衊蓋 (製膚選廠觸觸觸選鹹餘 ) 更多	积极	2019-03-01
				Placebo	廠網鹽糧範網網膚構鑰(衊獵淵網簾廠築齋鹽鹹) = 蓋積鏇膚鬱網顧廠蓋選憲範淵壓築築餘壓衊蓋 (製膚選廠觸觸觸選鹹餘 ) 更多